Opdivo nivolumab: Phase II data

Top-line data from the open-label, international Phase II CheckMate -275 trial in 270 patients with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum-containing regimen in the metastatic setting or within 1 year after neoadjuvant or adjuvant platinum therapy showed that 3 mg/kg IV Opdivo every 2 weeks led to an ORR of 19.6% and a median PFS and OS of 2 and 8.74 months, respectively. In patients with >=1% PD-L1 tumor expression, Opdivo led to an ORR of 23.8%, a median PFS of 3.55 months and a median OS of 11.3 months. In patients with <1% PD-L1 tumor expression, Opdivo led to an ORR of 16.1%, a median PFS of 1.87 months and a median OS of 5.95 months. Data were presented at the European Society for Medical Oncology meeting in Copenhagen...